A hedge fund manager and his battalion of scientists are hunting down a cure for Spinal Muscular Atrophy

A new $490 million business deal pits pharmaceutical companies against each other in a race to develop drugs for a rare genetic disease: Spinal Muscular Atrophy (SMA). One in 8,000 babies is born with SMA compared to one in 4,000 born with Cystic Fibrosis, a similar degenerative disease that has garnered much more public attention and fundraising.